Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2184
Thu, 02.09.2021
Epigenomics AG
New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations
The availability of blood based mSEPT9 tests, such as Epi proColon(R), increased the rate of testing to 93.5%, from 12.6% with fecal immunochemical testing (FIT) in prior years
Epi proColon cu [ … ]
Tue, 24.08.2021
Epigenomics AG
NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA
Press Release / Advertising
Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin
Berlin, Germany, August 24, 2021 - Epigen [ … ]
Fri, 20.08.2021
Epigenomics AG
NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA
Publication of inside information pursuant to Article 17 MAR
Reduction of principal amount of planned mandatory convertible bond to up to EUR 16.5 million and of conversion price to EUR 1.10 per share
Berlin, German [ … ]
Tue, 17.08.2021
Epigenomics AG
Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance
Berlin, Germany, August 17, 2021 - Today Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") has entered into an agreement with New Horizon Health Limited (6606.HK) on the sale of certain non-essential biological samples. Gross proceeds from the sa [ … ]
Wed, 11.08.2021
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Six Months of 2021
Berlin (Germany) and San Diego, CA (U.S.A.), August 11, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2021.
OPERATIONAL DEVELOPMENTS
Epigenomics AG has two options [ … ]
Fri, 11.06.2021
Epigenomics AG
NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA
Publication of inside information pursuant to Article 17 MAR
Epigenomics AG plans to issue mandatory convertible bond in the amount of up to EUR 18.15 million
Berlin, Germany, June 11, 2021 - The Executive Board of [ … ]
Tue, 18.05.2021
Epigenomics AG
NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA.
Epigenomics AG successfully completes capital increase
Berlin, 18 May 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY, the "Company") has fully placed the new shares from the capital increase resolved on Apr [ … ]
Wed, 12.05.2021
Epigenomics AG
Press release
Epigenomics AG Reports Financial Results for the First Quarter of 2021
Berlin (Germany) and San Diego, CA (U.S.A.), May 12, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2021.
Financial key figures
Product revenue in the first quarter [ … ]
Tue, 27.04.2021
Epigenomics AG
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA.
Press release
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Berlin, 27 April 2021 - On 27 April 2021, the Executive Boa [ … ]
Tue, 27.04.2021
Epigenomics AG
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA.
Publication of inside information pursuant to Article 17 MAR
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Berlin, 27 A [ … ]